Founder & CEO

Kevin Slawin, MD

Kevin Slawin, MD. is the Founder and Managing Partner of Rapha Capital Management, LLC. He is a successful and experienced oncologic and robotic surgeon, biotech consultant, investor, and founder focusing on disruptive technologies in oncology, T cells and immunotherapy, as well as other breakthrough healthcare technologies. He is the founder of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) leading Bellicum to a successful $161 million IPO in December, 2014. He also plays a guiding role in several of the investments managed by Rapha Capital in certain companies, serving as a board member at 3DBio Therapeutics, Inc. (https://3dbiocorp.com/), FIZE Medical, Inc. (https://fizemedical.com), Demeetra AgBio, Inc. (https://demeetra.com) and Imagin Medical, Inc. (https://imaginmedical.com). He served as a board member and interim CEO of portfolio company AsclepiX Therapeutics, Inc. (https://asclepix.com) in 2020, engineering their $35 million Series A financing led by Perceptive Xontogeny Venture Fund in mid 2020. Rapha Capital Management manages thirteen legacy SPIVs, Rapha Capital Investment I – XIII. Rapha Capital Management will be offering alternative asset management services to its inaugural venture capital fund, which will be the vehicle for all future investments managed by Rapha Capital Management.

 

He is also the founder and CEO of Ponce Therapeutics, Inc. (https://poncetherapeutics.com), which reunites the team that founded Bellicum Pharmaceuticals and is retooling their original cell control technology with state-of-the-art advances towards creating anti-aging products based on a scientific foundation, and DELiver Therapeutics, Inc. (https://delivertherapeutics.com), which is using novel, high throughput screening technologies to deliver therapeutics to address the most difficult problems in clinical medicine. Both have R&D facilities located at K2Bio in Houston (https://www.k2-biolabs.com/), a coworking research facility for biotech and pharma startups recently opened in Houston, where he is a co-founder, investor, and board member.

Slawin graduated magna cum laude with a Bachelor of Arts degree in Biochemistry from Columbia University, where he was inducted into Phi Beta Kappa. He earned his medical degree in 1986 from Columbia College of Physicians and Surgeons and was elected to the Alpha Omega Alpha honor society. He trained in General Surgery and then Urology at the Mount Sinai Hospital and at Squier Urologic Clinic at Columbia Presbyterian Hospital, both in NYC. Later, he was awarded a two-year fellowship, from 1992-1994, as an American Foundation of Urologic Disease (AFUD) scholar at Baylor College of Medicine to continue to study the development and treatment of prostate cancer under the tutelage of renowned prostate cancer surgeon and thought leader, Dr. Peter Scardino. Slawin joined the Baylor College of Medicine as Director of The Baylor Prostate Center in 1994 and was appointed the Dan Duncan Family Professor in Prostate Cancer and Prostatic Diseases in 2003, established by the well-known Houston oil man and philanthropist of the same name. He is co-Inventor of the FDA-approved “prostate health index (phi)” test licensed and marketed by Beckman Coulter and utilized around the world. He has published extensively in top medical and scientific journals including the Journal of the American Medical